Total Payments
$543,418
2024 Payments
$65,728
Companies
54
Transactions
1,735
Medicare Patients
7,179
Medicare Billing
$7.1M
Payment Breakdown by Category
Other$223,912 (41.2%)
Research$127,525 (23.5%)
Consulting$105,995 (19.5%)
Travel$48,661 (9.0%)
Food & Beverage$36,952 (6.8%)
Education$373.31 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $218,023 | 111 | 40.1% |
| Unspecified | $127,525 | 36 | 23.5% |
| Consulting Fee | $105,995 | 60 | 19.5% |
| Travel and Lodging | $48,661 | 155 | 9.0% |
| Food and Beverage | $36,952 | 1,354 | 6.8% |
| Honoraria | $5,650 | 2 | 1.0% |
| Education | $373.31 | 16 | 0.1% |
| Grant | $239.52 | 1 | 0.0% |
Payments by Type
General
$415,893
1,699 transactions
Research
$127,525
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $113,190 | 331 | $0 (2024) |
| Amgen Inc. | $106,395 | 232 | $0 (2024) |
| GENZYME CORPORATION | $95,374 | 163 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $50,124 | 91 | $0 (2024) |
| GlaxoSmithKline, LLC. | $34,586 | 40 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32,950 | 57 | $0 (2024) |
| SANOFI US SERVICES INC. | $19,404 | 10 | $0 (2018) |
| Janssen Biotech, Inc. | $15,936 | 98 | $0 (2024) |
| Eli Lilly and Company | $12,555 | 7 | $0 (2021) |
| Ironwood Pharmaceuticals, Inc | $12,400 | 26 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,728 | 264 | GENZYME CORPORATION ($24,578) |
| 2023 | $71,032 | 203 | ABBVIE INC. ($23,020) |
| 2022 | $57,238 | 242 | ABBVIE INC. ($32,526) |
| 2021 | $23,292 | 193 | AbbVie Inc. ($11,786) |
| 2020 | $26,570 | 128 | Eli Lilly and Company ($6,789) |
| 2019 | $54,648 | 195 | AbbVie, Inc. ($19,512) |
| 2018 | $162,245 | 285 | Amgen Inc. ($79,663) |
| 2017 | $82,664 | 225 | E.R. Squibb & Sons, L.L.C. ($19,887) |
All Payment Transactions
1,735 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $39.74 | General |
| Category: Rheumatology | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,675.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Biosimilars | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $144.55 | General |
| Category: Immunology | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $21.32 | General |
| 12/10/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/06/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $36.47 | General |
| Category: Rheumatology | ||||||
| 12/05/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $38.29 | General |
| Category: Rheumatology | ||||||
| 12/05/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.93 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $4.66 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $31.72 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.93 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Etanercept monotherapy in PsA | Amgen Inc. | $68,206 | 8 |
| TARGET: Treatments Against RA and Effect on FDG PET-CT | Amgen Inc. | $33,422 | 1 |
| Rheumatoid Arthritis Sarilumab | SANOFI US SERVICES INC. | $19,404 | 10 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COSENTYX SECUKINUMAB 150 MG IN ADULT SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER 16 WEEKS OF TREATMENT COMPARED TO PLACEBO | Novartis Pharmaceuticals Corporation | $1,731 | 1 |
| AC-064A201-LUPUS | Actelion Pharmaceuticals, Ltd | $1,500 | 1 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | AbbVie Inc. | $1,231 | 8 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $708.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $692.31 | 2 |
| A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | Eli Lilly and Company | $300.00 | 1 |
| A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | PFIZER INC. | $283.50 | 1 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $30.60 | 1 |
| A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $16.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,345 | 98,287 | $3.3M | $1.2M |
| 2022 | 23 | 1,657 | 95,902 | $3.2M | $1.4M |
| 2021 | 25 | 2,020 | 108,694 | $4.1M | $2.1M |
| 2020 | 27 | 2,157 | 142,867 | $4.8M | $2.3M |
Total Patients
7,179
Total Services
445,750
Medicare Billing
$7.1M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 30 | 14,675 | $1.2M | $494,472 | 39.6% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 25 | 58,400 | $630,800 | $228,512 | 36.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 132 | 11,640 | $512,940 | $214,365 | 41.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 13 | 10,460 | $276,760 | $110,798 | 40.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 391 | 774 | $209,074 | $69,831 | 33.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 67 | 399 | $137,655 | $38,625 | 28.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 157 | 576 | $108,864 | $30,864 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 90 | 145 | $52,937 | $19,674 | 37.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 69 | 170 | $34,475 | $8,850 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $11,983 | $3,738 | 31.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 187 | 415 | $8,300 | $3,486 | 42.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 49 | $9,102 | $3,425 | 37.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 117 | $12,870 | $2,507 | 19.5% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 70 | 363 | $4,356 | $1,826 | 41.9% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 23 | 45 | $6,975 | $959.00 | 13.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 22 | $5,940 | $894.96 | 15.1% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 12 | 14 | $560.00 | $172.90 | 30.9% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 32 | 17,600 | $1.3M | $607,232 | 46.6% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 24 | 48,820 | $537,020 | $223,121 | 41.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 132 | 12,900 | $367,080 | $221,397 | 60.3% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 13 | 11,400 | $273,600 | $134,274 | 49.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 472 | 1,050 | $284,252 | $95,866 | 33.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 67 | 388 | $133,860 | $38,662 | 28.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 150 | 486 | $91,854 | $27,010 | 29.4% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2022 | 15 | 1,440 | $35,338 | $19,206 | 54.3% |
About Dr. Robert Levin, M.D
Dr. Robert Levin, M.D is a Rheumatology healthcare provider based in Clearwater, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326066903.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Levin, M.D has received a total of $543,418 in payments from pharmaceutical and medical device companies, with $65,728 received in 2024. These payments were reported across 1,735 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($218,023).
As a Medicare-enrolled provider, Levin has provided services to 7,179 Medicare beneficiaries, totaling 445,750 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Clearwater, FL
- Active Since 07/18/2006
- Last Updated 07/21/2021
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326066903
Products in Payments
- Enbrel (Biological) $103,724
- RINVOQ (Biological) $64,778
- KEVZARA (Drug) $62,953
- ORENCIA (Biological) $43,348
- BENLYSTA (Biological) $34,229
- KEVZARA (Biological) $33,135
- SKYRIZI (Biological) $19,669
- NO PRODUCT DISCUSSED (Drug) $19,404
- Rinvoq (Biological) $16,947
- OFEV (Drug) $15,621
- DUZALLO (Drug) $12,349
- TREMFYA (Drug) $11,806
- Uloric (Drug) $4,800
- COSENTYX (Drug) $4,085
- Humira (Biological) $4,027
- STELARA (Biological) $3,981
- KRYSTEXXA (Biological) $3,377
- COSENTYX (Biological) $3,366
- Hymovis (Device) $2,531
- EVUSHELD (Drug) $1,992
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Clearwater
Adam Rosen, Md, MD
Rheumatology — Payments: $410,189
Rheumatology $410,189
Eugenia Rullan Bidot, Md, MD
Rheumatology — Payments: $22,536
Rheumatology $22,536
Sari Edelman, Do, DO
Rheumatology — Payments: $16,648
Rheumatology $16,648
Dr. David Gray, M.d, M.D
Rheumatology — Payments: $10,827
Rheumatology $10,827
Maria Skopis, Do, DO
Rheumatology — Payments: $5,371
Rheumatology $5,371